论文信息 - The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study - 字舞流文

The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study

L. Staudt | W. Wilson | R. Advani | George E. Wright | S. Pittaluga | Mickey P. Williams | R. Schmitz | K. Blum | J. Gerecitano | A. Goy | J. Buggy | Yandan Yang | P. Barr | V. Kenkre | A. Shustov | S. Balasubramanian | M. Cheng | S. Vos | L. Kunkel | J. McGreivy | J. Lih | D. Moussa | J. Mcgreivy | W. Wilson